REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

Gleich Webcast http://ir.redhillbio.com/events

RedHill Biopharma (NASDAQ: RDHL) today reported its financial results and operational highlights for the first quarter ended March 31, 2021. · Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance of approximately $92 million as of March 31, 2021, compared to approximately $115 million as of March 31, 2020 · Talicia® prescription volume grew 11% versus previous quarter; Movantik® new prescriptions in the first quarter 4% higher than Q1/2020 · Opaganib global Phase 2/3 study almost 100% enrolled · Management to host webcast today, at 8:30 a.m. EST Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19 therapeutics development. Opaganib, one of the most advanced and promising novel, dual-mode of action, oral drug candidates in development for COVID-19, now has almost 100% enrollment in its global 464-patient Phase 2/3 study in severe COVID-19.” Mr. Ben-Asher continued: “Commercially, a strong end to the first quarter has set up 2021 for growth, reversing a slow start to the year across the industry. Movantik’s new prescriptions in the first quarter outperformed the same quarter last year, while Talicia’s growth in prescription volume, repeat prescribing and new prescribers will be key growth drivers going forward. With the U.S. now emerging from the shadows of COVID-19, patients returning to clinics and travel resuming, positively affecting Aemcolo’s prospects, we are excited for the promise 2021 holds.” Micha Ben Chorin, Chief Financial Officer at RedHill, added: “A strong March helped rebalance quarterly revenues, as we maintained cash burn rate at previous quarter levels. With a healthy balance sheet, we are well-positioned to drive our late-stage R&D programs forward, as we work diligently to build on the upward trends across our core business.”

https://seekingalpha.com/pr/18335633-redhill-biopharma-reports-first-quarter-2021-financial-results-and-operational-highlights

@JST_BY: Also sooo wohltätig sehe ich mich dann doch nicht ;-) . Natürlich freue ich mich über jedes gerettete Leben, wenn ich allerdings schon mein Geld für die Entwicklung/Weiterentwicklung des Unternehmens zur Verfügung stelle dann erwarte ich mir aber auch einen entspechenden ROI - sonst wäre ich kein Investor;-) - also für mich MUSS das Hand in Hand gehen :-D

Mir persönlich geht es darum dass das Medikament wirkt. Dann freue ich mich wenn es Leben rettet. Vllt kommen paar Euro aufs Konto aber das ist nicht so wichtig

Die FDA - so glaube ich - braucht wahrscheinlich weitere Daten um den Impferfolg nicht zu gefährden. Wenn es ein super wirksames Medikament gibt, würden natürlich auch etliche „nicht so ganz impfwillige“ Menschen auch etwas zurück lehnen und sich bei einer Infektion und einem etwaigen schweren Verlauf auf Opaganib verlassen. Und das Ziel ist ja von jedem Land mindestens 70-80 Prozent der Bevölkerung zu impfen. Bei der FDA dürfte mittlerweile allen klar sein, dass Opaganib überragend gegen covid ist.

ich denke der kurzfristige Target-Markt wird Europa und Südamerika sein. Anscheinend benötigt die FDA noch zusätzliche Daten um eine EUA-Zulassung zuzulassen. Sollte aber dem Erfolg des Medikamentes (uns Aktionären) nicht großartig im Weg stehen ;-)

So jetzt nehmen wir erstmal alle Ungläubigen raus die ihre EK‘s retten wollen und dann kann es losgehen 😊

Gegen zweistellig wäre nichts einzuwenden...

Das muss jetzt erst mal 15:30 überstehen. Aber hier sollte einfach Mal nachhaltig zweistellig angepeilt werden. Die Welt braucht das Medikament!

Geht doch so langsam los...

alle Vorbereitungen sind abgeschlossen, jetzt brauchen wir nur noch die Zündung 🤓🚀

RedHill Biopharma (Nasdaq: RDHL) announces receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib and RHB-107 (upamostat) as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus. The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted. · The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted · Enrollment in opaganib’s global Phase 2/3 study in hospitalized patients with severe COVID-19 is almost 100% complete · RHB-107’s ongoing Phase 2/3 study is enrolling U.S. non-hospitalized patients with symptomatic COVID-19 that do not require supplemental oxygen · Opaganib and RHB-107 are novel, oral, host-targeted drug candidates expected to be effective against emerging viral variants · Opaganib and RHB-107 potentially cover the vast majority of affected COVID-19 patients “There is an urgent need for oral COVID-19 treatments for patients inside and outside of the hospital setting,” said Danielle T. Abramson, Ph.D., VP, Intellectual Property & Research at RedHill. “With two novel oral COVID-19 therapeutics in late clinical-stage development, RedHill stands at the forefront of research for COVID-19 treatments. We are very pleased with the new intellectual property protection which extends until at least 2041. The Company has also filed for protection under the Patent Cooperation Treaty (PCT) and has the option of applying in the member countries thereof.”

RedHill Biopharma (Nasdaq: RDHL) announces presentation of new analyses of Aemcolo® (rifamycin) and Movantik® (naloxegol) data at Digestive Disease Week (DDW) 2021. The Company presented three posters: Aemcolo poster (poster number: Fr244): Development of a New Travelers’ Diarrhea (TD) Clinical Severity Classification and its Utility in Confirming Rifamycin SV Efficacy “Antibiotics are the mainstay of treating bacterial TD; due to growing resistance, they should be reserved for use in more severe cases of the disease,” said Professor Herbert L. DuPont, Director of the Center for Infectious Diseases, University of Texas Houston School of Public Health. “In order to help direct treatment to the most appropriate patients, we developed a new severity classification tool able to support accurate prognosis of disease course and resolution, based on extensive patient data from two Phase 3 trials in Travelers’ Diarrhea, providing significant potential clinical utility. We then used the new classifications to assess the efficacy of rifamycin, reconfirming highly statistically significant efficacy across both newly reclassified moderate and severe patient groups.” Movantik posters: Poster 1 (Poster Number: Sa059): Naloxegol Achieved Rapid and Sustained Improvement of Opioid-Induced Constipation (OIC) Symptoms: A Pooled Analysis of Two Global Randomized Placebo-Controlled Trials Poster 2 (Poster Number: Sa058): Rapid Onset of Time to First Spontaneous Bowel Movement (SBM) and Predictable Efficacy of Naloxegol: Pooled Analysis of Two Global Randomized Controlled Trials “These two new analyses demonstrate rapid and sustained efficacy of naloxegol for a broad range of bothersome OIC symptoms, positively impacting patient care. Given the challenge of OIC symptoms, early symptom relief is an important therapeutic consideration” said Prof. William D. Chey, Director of the GI Physiology Laboratory at the University of Michigan, and former Co-Editor-in-Chief of the American Journal of Gastroenterology.

Immerhin nähern wir uns allmählich der 6€ 😁

Bin wieder bei meinem EK 🎉🍻👍🤪